Milestone Pharmaceuticals stock stays near $0.92 after China approval

Milestone Pharmaceuticals stock (US60041A1025) closed at $0.92 on Nasdaq on September 18, 2026, down 0.41 percent, with a market value of $114.02 million and volume of 562,522 shares. MarketBeat lists a consensus price target of $6.40 and a Moderate Buy rating.

China approval drives cash flow

MarketBeat says Milestone reported quarterly EPS of -$0.21 on August 12, 2026, missing the consensus estimate by $0.02, while revenue reached $0.56 million versus $0.82 million expected. The same page also notes that earnings are expected to improve from -$0.84 per share to -$0.77 per share in the coming year.

On September 3, 2026, MarketBeat also highlighted the China approval for etripamil nasal spray in PSVT, which triggered a $2 million milestone payment. For investors, that payment matters because it gives the approval a direct near-term financial effect, even as the stock still trades far below the consensus target.

Guidance still points lower losses

The latest company overview on Milestone Pharmaceuticals' investor site says the group uses a lean cost model and focuses on cardiovascular drug development, with etripamil as the lead program. MarketBeat adds that the stock has a 52-week range of $0.88 to $3.06, so the September 18 close sat close to the yearly low.

MarketBeat also shows short interest at 14.68 percent of float and a days-to-cover ratio of 11.34, while institutions hold 86.18 percent of the shares. That mix leaves the stock sensitive to both clinical news and position changes.

Stock near yearly low

Milestone Pharmaceuticals stock closed at $0.92 on Nasdaq on September 18, 2026, against a 52-week range of $0.88 to $3.06. The shares also trade well below the $6.40 consensus target that MarketBeat lists for September 19, 2026.

More news and analyses on Milestone Pharmaceuticals stock